American Century Companies Inc. Has $3.51 Million Stake in Teva Pharmaceutical Industries Ltd. $TEVA

American Century Companies Inc. increased its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 5.5% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 228,420 shares of the company’s stock after purchasing an additional 11,897 shares during the quarter. American Century Companies Inc.’s holdings in Teva Pharmaceutical Industries were worth $3,511,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in TEVA. Migdal Insurance & Financial Holdings Ltd. raised its position in shares of Teva Pharmaceutical Industries by 1.2% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,335,422 shares of the company’s stock valued at $404,775,000 after purchasing an additional 300,000 shares during the period. Harel Insurance Investments & Financial Services Ltd. grew its stake in Teva Pharmaceutical Industries by 197,885.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company’s stock valued at $338,989,000 after buying an additional 22,044,407 shares during the last quarter. Duquesne Family Office LLC grew its stake in Teva Pharmaceutical Industries by 530.1% in the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company’s stock valued at $198,303,000 after buying an additional 7,569,450 shares during the last quarter. Janus Henderson Group PLC raised its holdings in Teva Pharmaceutical Industries by 40.6% in the 4th quarter. Janus Henderson Group PLC now owns 6,737,625 shares of the company’s stock worth $148,497,000 after acquiring an additional 1,945,688 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its position in Teva Pharmaceutical Industries by 472.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company’s stock worth $96,078,000 after acquiring an additional 5,186,592 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on TEVA. Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. UBS Group decreased their target price on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, June 26th. Bank of America lifted their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. The Goldman Sachs Group initiated coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a “buy” rating and a $24.00 price target for the company. Finally, JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $21.00 to $23.00 in a research note on Monday, May 12th. Two analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $24.71.

Teva Pharmaceutical Industries Trading Up 2.0%

Teva Pharmaceutical Industries stock opened at $18.41 on Friday. The business has a 50 day moving average price of $16.86 and a two-hundred day moving average price of $16.32. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. The stock has a market cap of $21.11 billion, a price-to-earnings ratio of -115.04, a price-to-earnings-growth ratio of 1.09 and a beta of 0.62. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.Teva Pharmaceutical Industries’s revenue for the quarter was up .3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 52,742 shares of the business’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Placid Jover sold 6,053 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the transaction, the insider owned 6,774 shares of the company’s stock, valued at approximately $102,693.84. This represents a 47.19% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 65,001 shares of company stock worth $996,958 over the last 90 days. Corporate insiders own 0.49% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.